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Background: The study evaluated the impact of health insurance status and mode of
arrival to the emergency department (ED) on in-hospital outcome of patients with
ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous interven-
tion.
Methods: 452 consecutive patients presenting with STEMI from 01/2010 to 03/2012 in
a community hospital were included in this retrospective study. Demographic, procedural
and pre-discharge mortality data were collected on all patients. Health insurance status
(insured or uninsured) and mode of arrival (by emergency medical service (EMS) or by
self-transport) were recorded.
Results: Out of 452 patients, 18.4% patients had no insurance and 44% patients arrived
by self-transport. Patient with no insurance were younger (6211 vs 66 12 years,
p0.03) and more likely to be smokers (48% vs 29%, P0.002) compared to patients
with insurance coverage. There was no difference in gender, medical co-morbidities,
LVEF, and door-to-balloon time between patients with or without health insurance or
those arriving by ambulance or self transport. Uninsured patients were more likely to
arrive by self transport rather than utilizing EMS (P0.001) and more likely to arrive in
the evening or night hours (5PM-7AM)(p0.001) compared with those with health
insurance. Door-to-balloon time, LVEF and incidence of major bleeding events did not
differ with insurance status or mode of arrival. In-hospital mortality was higher in
uninsured patients (15.7% vs 2.8%, p0.0001). Door to balloon time was also a
significant predictor of in-hospital mortality. Mode of arrival did not influence mortality.
Multivariate analysis identified door to balloon time and health insurance status to be
independent predictors of in-hospital mortality(p0.001).
Conclusions: Uninsured patients with STEMI have a higher probability of not utilizing
essential health care resources such as EMS and presenting during off hours. They also
have a significantly higher in-hospital mortality compared to those with health insurance,
likely due to absence of long term, preventive health care.
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Background: High sensitivity C-reactive Protein (hs-CRP)elevation is associated with
cardiovascular events in the healthy general population as well as in patients with
coronary artery disease. However, the prognostic value of hs-CRP elevation before
coronary stent implantation remains debated regarding ST especially in acute myocardial
infarction (AMI) patients. This study examined whether hs-CRP elevation may predict
stent thrombosis (ST).
Methods: A total of 7969 AMI patients who underwent coronary stent implantation with
drug eluting stent (mean age  64.3  12.4 years, 5838 males, 5408 ST elevation MI,
2561 non ST elevation MI) were analyzed in the Korean Acute Myocardial Infarction
Registry. During clinical follow-up of 12months, major adverse cardiac events (MACE),
and ST were evaluated.
Results: 133 STs (1.4%) were developed during 12 months (acute ST: 10 patients,
subacute ST: 72 patients, late ST: 38 patients). The incidence of total ST had increased as
level of hs-CRP had increased. [1st quartile (0  hs-CRP  0.9 mg/L) : 0.7%, 2nd
quartile (0.9  hs-CRP  2.6 mg/L) : 1.1%, 3rd quartile (2.6  hs-CRP  6.3 mg/L) :
1.5%, 4th quartile (hs-CRP  6.3 mg/dL) : 1.7%, p  0.008]. In a multivariable logistic
regression analysis, the level of hs-CRP greater than 2.0 mg/L [p0.001, hazard ratio
(HR): 2.36, 95% confidence interval (CI): 1.47-3.80], many number of implanted stents
(p0.002, HR: 1.357, 95% CI: 1.12-1.65), old age (p0.020, HR: 1.02, 95% CI:
1.01-1.03) were independent predictors of ST.
Conclusions: High hs-CRP levels ( 2.0 mg/L) before coronary stent implantation in
AMI patients are associated with risk of ST. These data suggest that pre-procedural
hs-CRP is a predictor of stent thrombosis.
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Background: Persistent ST elevation(STE) on ECG after acute STE myocardial
infarction (MI) has been considered a marker of persistent wall motion abnormalities-
(WMA) or aneurysm in the region of MI. However, the echocardiographic correlation of
persistent STE has not been studied in percutaneous coronary intervention (PCI) era. We
sought to evaluate the significance of persistent STE in patients undergoing PCI for
STEMI.
Methods: Consecutive patients undergoing revascularization for first STEMI at a tertiary
center from July 2007 to June 2010 were included. Patients who died during the
hospitalization, had coronary vasospasm, clinical post-MI pericarditis or bundle branch
block on ECG were excluded. Presentation, discharge and follow up ECGs were
reviewed. STE was defined as presence of 0.5 mm of STE in standard limb or precordial
leads. Echocardiograms done within 2 days of MI, and on follow-up post-discharge were
reviewed for presence of WMA in the region corresponding to STE.
Results: 170 patients were considered after exclusion criteria were met. Follow-up
echocardiograms were available in 126 patients who were included in final analysis
(76.2% males; mean age 61.9 years). Persistent STE was noted in 38(30.1%) patients at
discharge and in 30(23.8%) patients on follow up. Q-waves were noted in 64(50.8%)
patients at discharge. Corresponding WMA were present in 95(75.4%) patients on initial
echocardiogram and persisted in 54(42.8%) patients on follow-up echocardiogram.
Aneurysm or dyskinesis was not seen in any patient with persistent STE. Presence of STE
at discharge and follow up, as well as Q waves at discharge correlated significantly with
persistence of significant WMA other than dyskinesis on follow up (p values0.001). The
sensitivity and specificity for predicting persistent WMA on follow-up were 61.1% and
93% for STE at discharge, 49.1% and 94.4% for STE at follow-up and 72.2% and 65.3%
for Q waves at discharge.
Conclusions: Persistent STE on ECG is not uncommon at discharge and on follow-up in
patients undergoing PCI for STEMI, and does not predict development of aneurysm.
Persistent STE at discharge or follow-up is a highly specific marker of persistent WMA
in region of STEMI despite PCI.
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Background: ST-segment elevation resolution (STR) has been shown to correlate with
infarct- related artery patency and prognosis post myocardial infarction (MI). However,
which STR method best predicts infarct size is unclear.
Methods: The INFUSE-AMI trial randomized patients with STEMI due to proximal or
mid LAD occlusion to intracoronary bolus abciximab (ClearWay RX catheter) vs. no
abciximab, and to thrombus aspiration (Export) vs. no aspiration. ECGs with quantitative
ST segment analysis were performed at baseline and 60 minutes post intervention. MRI
infarct size as percentage of total LV mass was calculated 30 d post intervention. ECGs
and MRIs were read at independent core laboratories. The following STR methods were
analyzed for their ability to predict MRI infarct mass: 1. Summed %STR across all infarct
related ECG leads (STR), stratified as 30, 30-70, or 70% (strata A, B, C) 2. %STR
in the single lead with maximum baseline ST elevation (max STR), also stratified as30,
30-70, or70% (A, B, C) 3. Summed residual ST elevation across all infarct related leads
at 60 min post intervention (ST residual), stratified as 2, 2-4, 4 mm (A,B,C) 4.
Maximum residual ST elevation in single lead at 60 min post (max ST residual), stratified
as 1, 1-3, or 3mm (A,B,C) 5. New Q waves at 60 min, stratified as 0, 1-3, or 3
(A,B,C).
Results: All STR methods correlated with MRI infarct mass at 30d. However, simpler
measures of STR such as residual ST elevation or new Q waves were as effective as more
complicated STR methods (Table).
Conclusions: Simpler methods of STR correlated with anterior infarct size in the
INFUSE-AMI study. In particular, max ST residual at 60 min is a simple method that may
offer rapid analysis for clinical management and prognostic significance.
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Table: Correlations between STR methods and infarct size
Spearman
rank A vs B A vs C B vs C
STR p0.0007 p0.75 p0.06 p0.009
max STR p0.0026 p0.76 p0.10 p0.06
ST residual p0.0001 p0.28 p0.0001 p0.0001
max ST residual p0.0001 p0.005 p0.0001 p0.0003
new Q waves p0.0001 p0.0001 p0.0001 p0.056
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Background: The HEBE study is a multicenter trial, where 200 patients with large first
AMI treated with primary percutaneous coronary intervention were randomly assigned to
either intracoronary infusion of mononuclear bone marrow (BMMC) cells (n69),
mononuclear peripheral blood cells (PBMC) (n66), or standard therapy (n65). At 4
months, regional or global systolic myocardial function improved in all groups, with no
significant difference between groups. Here, we conducted a 2 year magnetic resonance
imaging (MRI) follow-up.
Methods: In addition to 3-5 days after AMI, 4 months, patients underwent MRI at 2 years
after myocardial infarction and mononuclear cell infusion. All MRI analyses were
performed in a core laboratory using a standardized protocol and blinded for treatment
assignment.
Results: The percentage of dysfunctional left ventricular (LV) segments that improved
during 2 years of follow-up, did not differ significantly between BMMC and control:
(45.026.3% in the BMMC group, and 52.322.6% in the control group (p0.14).
However, the percentage was significantly lower in the PBMC group, 42.520.7%,
p0.03. Furthermore, there was less increase in LVEDV for BMMC (3.516.9 mL/m2)
compared to control (11.219.8 mL/m2, p0.03). The 3 groups did not differ in changes
in LVESV, LV mass and had similar rates of clinical events.
Conclusions: Intracoronary infusion of PBMCs and BMMC following AMI does not
improve recovery of myocardial function in the HEBE trial at 2-years of follow-up. The
increase in LVEDV was lower in the BMMC group, suggesting a long-term beneficial
























45.026.3 42.520.7 52.322.6 0.14 0.03
LV ejection fraction
(%)
Baseline 43.79.0 41.79.1 42.48.3
24 months 49.28.1 44.910.3 47.79.4
Change 4.28.6 3.08.3 4.08.6 0.58 0.33
LV end-diastolic
volume (mL/m2)
Baseline 97.314.0 98.015.4 100.016.9
24 months 99.920.2 108.028.1 110.328.3
Change 3.516.9 9.220.9 11.219.8 0.03 0.63
LV end-systolic
volume (mL/m2)
Baseline 55.414.5 57.815.9 58.115.1
24 months 51.817.4 61.326.4 59.123.8
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Background: Recovery of stunned myocardium can occur within 1 month from the
onset of ST-elevation myocardial infarction (STEMI). We examined the predictors of
recovery from stunning in the INFUSE-AMI randomized trial.
Methods: INFUSE-AMI was a 22 factorial design trial in which patients with STEMI
and proximal or mid left anterior descending (LAD) coronary artery occlusion receiving
bivalirudin anticoagulation were randomized to (1) bolus intracoronary abciximab via the
ClearWay RX catheter vs. no abciximab and (2) manual aspiration with the Export
catheter vs. no aspiration. In a formal substudy MRI imaging at both 5 and 30 days was
performed in 174 patients. MRI analysis included 1) microvascular obstruction (MVO)
defined as a black area inside a zone of delayed enhancement, 2) infarction area, 3)
transmural extent of infarction, and 4) total stunning/remodelling score as a sum of
segmental functional change ()from 5 to 30 days (2marked recovery, 1mild
recovery, 0no change, 1worse).
Results: Overall, left ventricular ejection fraction (LVEF) increased by 2.37.0% from
5 to 30 days. Compared to pts with LVEFmedian (2.1%), pts with LVEFmedian
were older, more often female, and more often diabetic (Table). Both MVO as % of LV
mass and transmural extent of infarction trended lower in pts with better LV recovery.
Multivariable analysis indicated that the independent predictors of better LV recovery
were smaller % MVO (coefficient 0.53, p0.002) and female gender (coefficient 2.68,
p0.05).
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